Latest news with #Phreesia
Business Wire
5 days ago
- Business
- Business Wire
Phreesia Named to the 2025 Capterra Shortlist for Patient Engagement and Medical Scheduling
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia, a leader in patient intake, outreach and activation, has been named to the 2025 Capterra Shortlist in the Patient Engagement and Medical Scheduling categories. The Capterra Shortlist is an independent assessment that evaluates user reviews and online search activity to identify a list of market leaders that offer the top products in various software categories. "Being named to two of the 2025 Capterra Shortlists is an honor that reflects the positive reviews and feedback we receive from our healthcare provider clients,' said Phreesia CEO Chaim Indig. 'Our digital solutions help engage and empower patients to take a more active role their care, and this award is a welcome recognition of those efforts.' Phreesia has an overall rating of 4.3 out of 5 on Capterra, driven by direct feedback from clients. 'Phreesia has become an integral partner in the management of my practice. It allows us to focus more on providing quality care to our patients,' one practice director shared in a review on the Capterra site. Capterra uses exclusive data and trusted reviews from verified software users to build its Capterra Shortlist reports, which present a comprehensive view of products' recent popularity and ratings based on data from a defined timeframe. For more information on Phreesia, visit About Phreesia Phreesia is the trusted leader in patient activation, giving healthcare providers, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled approximately 170 million patient visits in 2024—1 in 7 visits across the U.S.—scale that we believe allows us to make meaningful impact. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives efficiency and improves healthcare outcomes. To learn more, visit
Business Wire
07-08-2025
- Business
- Business Wire
Phreesia Sets Release Date for Fiscal Second Quarter 2026 Results
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia, Inc. (NYSE: PHR) ('Phreesia') today announced that it will release its fiscal second quarter 2026 financial results after the close of market trading on Thursday, Sept. 4, 2025. Phreesia will issue a press release announcing its quarterly results and the company's quarterly stakeholder letter, both of which will be posted on its investor website at Phreesia will then hold a conference call to discuss its fiscal second quarter results starting at 5PM Eastern Time on the same day. To participate in the company's live conference call and webcast, please dial (800) 715-9871, or (646) 307-1963 for international participants, using conference code number 7404611, or visit the 'Events & Presentations' section of A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days. ABOUT PHREESIA Phreesia is a trusted leader in patient activation, giving healthcare providers, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled approximately 170 million patient visits in 2024—1 in 7 visits across the U.S.—scale that we believe allows us to make meaningful impact. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives efficiency and improves healthcare outcomes. To learn more, visit
Business Wire
30-07-2025
- Health
- Business Wire
New Research Illustrates Gaps in COPD Care and the Need for Better Patient-Provider Communication
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Patients with chronic obstructive pulmonary disease (COPD) face significant challenges, but conversations with healthcare providers can play a critical role in helping patients understand their condition, set realistic goals, ease symptom burden and improve their quality of life, according to new research from the COPD Foundation and Phreesia. COPD is a chronic and progressive lung disease that affects more than 16 million people in the United States and is the sixth leading cause of death. The study, published in Chronic Obstructive Pulmonary Diseases: The Journal of the COPD Foundation, with funding support from Verona Pharma, was based on voluntary surveys from 1,615 COPD patients in January 2025. Patients completed the survey on Phreesia's platform after checking in for their doctor appointments and providing consent. Patients reported significant symptom burden, with 43% of patients saying they experience COPD symptoms, including shortness of breath and fatigue, at least 24 days in a typical month and a quarter of patients reporting symptoms every day. Patients also reported significant impacts to their quality of life, with around two-thirds saying COPD had a moderate-to-great impact on their daily lives and half reporting a moderate-to-great impact on their emotional health. COPD also impacted patients' ability to work, with 15% saying they had lost a job due to their condition. Surveyed patients also reported barriers to medication. One in five patients reported not using any maintenance medications. Among those patients, 27% said they didn't think their COPD was severe enough and 27% said their provider had not recommended maintenance therapy. Seventy-one percent of patients who had not tried any COPD medications said they would be likely to try them. And among patients who had tried maintenance medications, 80% said it was because their doctor had recommended it. Despite this opportunity for patient-provider discussions around maintenance medications and other treatment options, the study found significant communication gaps between patients and their healthcare providers. Only 45% of patients reported having detailed discussions about their COPD symptoms with their providers, and 22% of patients said they provided little to no symptom detail during visits. Additionally, more than a third of patients reported having limited to no understanding of COPD. That percentage was even higher among Black patients and patients aged 45−64 years, 46% and 41% respectively, highlighting the potential for targeted interventions. 'These findings point to the urgent need to improve communication between patients and their providers and ensure conversations are as engaging, informative and productive as possible,' said David Mannino, MD, Co-Founder and Medical Director of the COPD Foundation and the study's lead author. 'Equipping patients with the right information and resources can help them take a more active role in their care and improve health outcomes.' 'Given what we know about the benefits of giving patients relevant, credible health information at the point of care, these results have important implications that can be used to support patients struggling with COPD,' said David Linetsky, Phreesia's President, Network Solutions. 'At Phreesia, we've seen firsthand that when patients have more meaningful conversations with their providers, it helps them manage their treatment and improves quality of life.' For more information on Phreesia, visit Phreesia is the trusted leader in patient activation, giving healthcare providers, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled approximately 170 million patient visits in 2024—1 in 7 visits across the U.S.—scale that we believe allows us to make meaningful impact. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives efficiency and improves healthcare outcomes. To learn more, visit
CNBC
08-07-2025
- Business
- CNBC
Indig: AI has been wildly effective for us, our providers, and patients
Chaim Indig, CEO and founder of Phreesia, joins "Worldwide Exchange" to discuss how AI streamlines care delivery, enables patient self-service, and positions Phreesia as a digital front door to healthcare.
Yahoo
30-05-2025
- Business
- Yahoo
Q1 Earnings Outperformers: Phreesia (NYSE:PHR) And The Rest Of The Healthcare Technology for Providers Stocks
Looking back on healthcare technology for providers stocks' Q1 earnings, we examine this quarter's best and worst performers, including Phreesia (NYSE:PHR) and its peers. The healthcare technology industry focuses on delivering software, data analytics, and workflow solutions to hospitals, clinics, and other care facilities. These companies enable providers to streamline operations, optimize patient outcomes, and transition to value-based care models. They boast subscription-based revenues or long-term contracts, providing financial stability and growth potential. However, they face challenges such as lengthy sales cycles, significant upfront investment in technology development, and reliance on providers' adoption of new tools, which can be hindered by budget constraints or resistance to change. Over the next few years, the sector is poised for growth as providers increasingly prioritize digital transformation and efficiency in response to rising healthcare costs and patient demand for seamless care. Tailwinds include the growing adoption of AI-driven tools for patient engagement and operational improvements, government incentives for digitization, and the expansion of telehealth and remote patient monitoring. However, headwinds such as tightening hospital budgets, cybersecurity threats, and the fragmented nature of healthcare systems could slow adoption. The 6 healthcare technology for providers stocks we track reported a mixed Q1. As a group, revenues beat analysts' consensus estimates by 3.4% while next quarter's revenue guidance was 0.7% below. Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 8.7% since the latest earnings results. Founded in 2005 to streamline the traditionally paper-heavy patient check-in process, Phreesia (NYSE:PHR) provides software solutions that automate patient intake, registration, and payment processes for healthcare organizations while improving patient engagement in their care. Phreesia reported revenues of $115.9 million, up 14.5% year on year. This print exceeded analysts' expectations by 0.6%. Overall, it was a strong quarter for the company with an impressive beat of analysts' EPS estimates and customer base in line with analysts' estimates. "Our fiscal year 2026 is off to a strong start. I am grateful to our team for their continued commitment to our mission, vision and values. I believe our performance is a reflection of our team truly living our values,' said CEO and Co-Founder Chaim Indig. The stock is down 2.2% since reporting and currently trades at $24.43. Is now the time to buy Phreesia? Access our full analysis of the earnings results here, it's free. Operating one of the largest healthcare group purchasing organizations in the United States with over 4,350 hospital members, Premier (NASDAQ:PINC) is a technology-driven healthcare improvement company that helps hospitals, health systems, and other providers reduce costs and improve clinical outcomes. Premier reported revenues of $261.4 million, down 8.9% year on year, outperforming analysts' expectations by 7.4%. The business had a very strong quarter with a solid beat of analysts' EPS estimates and an impressive beat of analysts' full-year EPS guidance estimates. Premier scored the biggest analyst estimates beat among its peers. The market seems happy with the results as the stock is up 10.8% since reporting. It currently trades at $22.75. Is now the time to buy Premier? Access our full analysis of the earnings results here, it's free. Formerly known as Apollo Medical Holdings until early 2024, Astrana Health (NASDAQ:ASTH) operates a technology-powered healthcare platform that enables physicians to deliver coordinated care while successfully participating in value-based payment models. Astrana Health reported revenues of $620.4 million, up 53.4% year on year, falling short of analysts' expectations by 2.5%. It was a slower quarter as it posted revenue guidance for next quarter meeting analysts' expectations and full-year EBITDA guidance slightly missing analysts' expectations. Astrana Health delivered the fastest revenue growth but had the weakest performance against analyst estimates and weakest full-year guidance update in the group. As expected, the stock is down 24% since the results and currently trades at $25.38. Read our full analysis of Astrana Health's results here. Driven by the vision of an "Autonomous Pharmacy" with zero medication errors, Omnicell (NASDAQ:OMCL) provides medication management automation and adherence tools that help healthcare systems and pharmacies reduce errors and improve efficiency. Omnicell reported revenues of $269.7 million, up 9.6% year on year. This number surpassed analysts' expectations by 3.7%. Taking a step back, it was a slower quarter as it recorded full-year EBITDA guidance missing analysts' expectations. The stock is down 2.2% since reporting and currently trades at $29.83. Read our full, actionable report on Omnicell here, it's free. Founded in 2011 to transform how healthcare is delivered to patients with complex needs, Evolent Health (NYSE:EVH) provides specialty care management services and technology solutions that help health plans and providers deliver better care for patients with complex conditions. Evolent Health reported revenues of $483.6 million, down 24.4% year on year. This print topped analysts' expectations by 4.9%. Aside from that, it was a mixed quarter as it also recorded full-year revenue guidance slightly topping analysts' expectations but a significant miss of analysts' EPS estimates. Evolent Health pulled off the highest full-year guidance raise but had the slowest revenue growth among its peers. The stock is down 31.5% since reporting and currently trades at $7.38. Read our full, actionable report on Evolent Health here, it's free. As a result of the Fed's rate hikes in 2022 and 2023, inflation has come down from frothy levels post-pandemic. The general rise in the price of goods and services is trending towards the Fed's 2% goal as of late, which is good news. The higher rates that fought inflation also didn't slow economic activity enough to catalyze a recession. So far, soft landing. This, combined with recent rate cuts (half a percent in September 2024 and a quarter percent in November 2024) have led to strong stock market performance in 2024. The icing on the cake for 2024 returns was Donald Trump's victory in the U.S. Presidential Election in early November, sending major indices to all-time highs in the week following the election. Still, debates around the health of the economy and the impact of potential tariffs and corporate tax cuts remain, leaving much uncertainty around 2025. Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Growth Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
